報價延遲最少15分鐘:2026/09/02 10:40 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
27.61 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.62/0.39
|
|
企業價值
52.71M
|
| 資產負債 |
|
每股賬面淨值
8.24
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
24.05M
|
|
每股收益
6.12
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers. |
